Literature DB >> 16627749

Alcohol use, vascular disease, and lipid-lowering drugs.

Genovefa D Kolovou1, Klelia D Salpea, Katherine K Anagnostopoulou, Dimitri P Mikhailidis.   

Abstract

Many epidemiological and clinical studies have shown that light-to-moderate alcohol (Alc) consumption is associated with reduced risk of coronary heart disease (CHD) and total mortality in middle-aged and elderly men and women. The plausible mechanisms for the putative cardioprotective effects include increased levels of high-density lipoprotein cholesterol, prevention of clot formation, reduced platelet aggregation, promotion of blood clot dissolution, and lowering of plasma lipoprotein (a) concentration. Individuals who need to be treated with lipid-lowering drugs, such as dyslipidemic or CHD patients, may benefit from these effects of Alc. Because hypolipidemic treatment is usually continued for life, an important issue is the suitability of Alc consumption in these patients. In the present review, the beneficial effects of Alc consumption on CHD risk, its side effects, and its safety and suitability when coadministered with hypolipidemic drugs are discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16627749     DOI: 10.1124/jpet.106.102269

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  4 in total

1.  Alcohol reduces airway hyperresponsiveness (AHR) and allergic airway inflammation in mice.

Authors:  Peter J Oldenburg; Jill A Poole; Joseph H Sisson
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-11-23       Impact factor: 5.464

2.  Effects of statin treatment with atorvastatin on urolithiasis-associated urinary metabolic risk factors: an experimental study.

Authors:  Mustafa Zafer Temiz; Emrah Yuruk; Kasim Ertas; Oguzhan Zengi; Atilla Semercioz
Journal:  Int Urol Nephrol       Date:  2017-12-02       Impact factor: 2.370

3.  Adopting moderate alcohol consumption in middle age: subsequent cardiovascular events.

Authors:  Dana E King; Arch G Mainous; Mark E Geesey
Journal:  Am J Med       Date:  2008-03       Impact factor: 4.965

Review 4.  Severe/Extreme Hypertriglyceridemia and LDL Apheretic Treatment: Review of the Literature, Original Findings.

Authors:  Olga Diakoumakou; Georgios Hatzigeorgiou; Nikos Gontoras; Maria Boutsikou; Vana Kolovou; Sophie Mavrogeni; Vassiliki Giannakopoulou; Genovefa D Kolovou
Journal:  Cholesterol       Date:  2014-12-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.